Imeik Technology Development Co (300896) Fair Value & Analysis
Healthcare · CN · Market cap 27.9B CNY
Fair value as of: Jul 9, 2026
From 26 valuation models · updated 32 days ago
Fair value updated Jul 9, 2026, revised from ¥77.95 to ¥72.53 (−7.0%) since Jun 24, 2026. Share price +20.6% over the past month.
A solid business, but screening 31% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥90.66). The favourable scenario is already priced in.
- Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥85.50 – ¥552.53 · fair‑value band ¥54.40 – ¥90.66 · the ¥105.26 price screens above the ¥72.53 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Imeik Technology Development Co (300896) currently trades at ¥105.26, while our model-based Fair Value estimate is ¥72.53, implying the stock looks roughly 31.1% overvalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Imeik Technology Development Co generated revenue of 2.4B CNY at a net margin of 47.3%. Revenue declined 4.5% year over year. It earns a return on equity of 13.8%. The balance sheet holds a net cash position of 1.2B CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥54.40 (bear case) to ¥90.66 (bull case); at ¥105.26, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -31%, 300896 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥186.15) versus Asset-Based (¥16.79). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China.
Full company description
Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate composite solution for injection; modified sodium hyaluronate gel for injection; medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel; and skin care products. It serves medical aesthetic institutions. The company was incorporated in 2004 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Imeik Technology Development Co reported revenue of ¥2.4B in FY2025 versus ¥1.4B in FY2021, a compound +13.7%/yr. Reported net income was ¥1.3B in FY2025, compounding +7.7%/yr from FY2021.
300896 screens 31% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Imeik Technology Development Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Imeik Technology Development Co (300896) overvalued or undervalued?
What is the fair value of 300896?
What is the quality score of 300896?
What is the revenue of Imeik Technology Development Co (300896)?
What is the net profit margin of 300896?
Does Imeik Technology Development Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Imeik Technology Development Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.